With the health care debate continuing, how can investors make money in the sector? Barbara Ryan, managing director and senior pharmaceuticals analyst at Deutsche Bank Securities, and Charles Boorady, health care providers analyst at Citigroup, shared their insights.   Read More

In U.S. President Barack Obama's speech to Asia-Pacific leaders at the APEC Summit in Singapore over the weekend, he highlighted the importance of a strong China economy in the context of global growth.   Read More

Investors, patients and activists, no doubt, hope they won't have to put out a mayday distress call, but as Dendrama's fate would have it, the company announced today that the Food and Drug Administration has assigned May Day as its decision day for the prostate cancer treatment Provenge.   Read More

Earlier this week I reported that Dr. Allen Taylor who ran the Abbott vs. Merck cholesterol drug study, which Abbott's drug Niaspan won, would only say that ABT has paid him more than $10,000 in lecture and consulting fees. But he wouldn't be any more specific than that.    Read More

VVUS this morning unveiled positive late-stage test results on the ED pill. The company touts that it takes effect in less than 30 minutes and it's out of your system within six hours or so.    Read More

When I do an interview with a clinical trial investigator I typically try to take care of what I call the "housekeeping" at the beginning or end.    Read More

Live TV is best when things are happening and news is breaking right now. It's immediate and often, hopefully, more compelling.    Read More

In U.S. President Barack Obama's speech to Asia-Pacific leaders at the APEC Summit in Singapore over the weekend, he highlighted the importance of a strong China economy in the context of global growth.   Read More

It doesn't always happen, but there is a common to-and-fro, push-and-pull, back-and-forth or whatever you want to call it between reporters and corporate PR folks. I don't particularly like that part of my job, but sometimes it just comes with the territory. I've got my job to do and they've got theirs. I get it.    Read More

Today starts a two-day FDA public hearing in Washington, DC on biopharma and social media. I decided not to go because talking heads in a meeting room just don't make for good TV. And this is just the first step in what is no doubt going to be a very long, involved policy-making process. But as it turns out, it looks like it might have been futile for me to try to attend anyway.    Read More